quinidine has been researched along with bs-181 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aboagye, EO; Ali, S; Alikian, M; Barbazanges, M; Barrett, AG; Blum, A; Brackow, J; Coombes, RC; Freemont, PS; Fuchter, MJ; Hazel, P; Heathcote, DA; Jogalekar, AS; Kanneganti, SK; Kroll, SH; Liotta, DC; Pace, RD; Patel, H; Periyasamy, M; Scheiper, B; Siwicka, A; Snyder, JP | 1 |
1 other study(ies) available for quinidine and bs-181
Article | Year |
---|---|
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Blood Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Female; Humans; In Vitro Techniques; Mice; Mice, Nude; Microsomes, Liver; Models, Molecular; Phosphorylation; Protein Binding; Pyrazoles; Pyrimidines; Stereoisomerism; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2010 |